Clinical application of recombinant erythropoietin in renal dialysis patients

L. F. Gimenez, P. J. Scheel

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


The advent of erythropoietin (EPO) can be considered one of the major advances over the past 10 years in the treatment of end stage renal disease (ESRD) patients who are receiving chronic maintenance dialysis. Not only has it resulted in freedom from transfusion dependency and elimination of the attendant risks, but it also has led to a significant improvement in the quality of life these patients are able to achieve within the physical and emotional limitations imposed by the multiple metabolic abnormalities, concomitant medical problems of ESRD, and the dialysis process itself.

Original languageEnglish
Pages (from-to)913-926
Number of pages14
JournalHematology/Oncology Clinics of North America
Issue number5
StatePublished - 1994


Dive into the research topics of 'Clinical application of recombinant erythropoietin in renal dialysis patients'. Together they form a unique fingerprint.

Cite this